NASDAQHealth CareMedical - DevicesSnapshot 2026-08-31
Reading LMRI? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (3q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 63% in its worst 12-month stretch.
View RiskLMRI's growth depends on increasing advanced outpatient imaging volume and achieving strong EBITDA. Revenue grew 5% year over year, and the latest quarter beat expectations. The stock trades at a premium compared to peers, suggesting the price reflects less growth than anticipated. If LMRI cuts guidance on the next call, that could negatively impact the stock. Peer multiples imply a price about 18% below where it trades (it looks expensive on this basis). Our read remains intact.
Trailing returns as of 2026-08-31. LMRI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering LMRI (as of Aug 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A consensus fair price across 5 valuation methods, at three horizons. As of 2026-08-31. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Advances: Achieve $234 to $242 million Adjusted EBITDA in 2026
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-08-31. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Joint venture expansion supports adjusted EBITDA target.
Advances: Increase advanced outpatient imaging volume
Record advanced modality volume supports growth in imaging.
Advances: Achieve $1.045 to $1.097 billion revenue in 2026
Steady results support revenue growth objective.
Advances: Achieve $1.045 to $1.097 billion revenue in 2026
Earnings beat supports revenue growth objective.
Joint venture supports revenue growth objective.
Buy rating indicates positive outlook on growth.
